Sort
15,842 grants matching “pancreatic cancer”
Multimodal Investigation of Cellular Adaptation Across Timescales
$1,380,568David Pincus · University Of Chicago · RM1 · FY2024 · GM
Repository Services for epidemiology studies
$1,380,084David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2017 · CA
IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)PERIOD OF PERFORMANCE: 05/01/2015 TO 04/30/2016
$1,379,356Brenda Hernandez · Hawaii Univ · N01 · FY2015 · CA
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer
$1,377,000Bolni Marius Nagalo · Univ Of Arkansas For Med Scis · DP2 · FY2024 · CA
Loma Linda University Center for Health Disparities Res*
$1,375,164Marino De Leon · Loma Linda University · P20 · FY2009 · MD
Great Lakes New England Clinical Validation Center
$1,374,531Dean E. Brenner · University Of Michigan At Ann Arbor · U01 · FY2016 · CA
Molecular signatures for liver cancer diagnosis and treatment stratification
$1,372,016Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
The Role of Cripto in the Pathogenesis of Breast and Colon Cancer
$1,371,196David Salomon · Basic Sciences · Z01 · FY2007 · CA
Health Effects Of Exposures In Agriculture
$1,368,560Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES
Comprehensive Cancer Center Core Support Grant
$1,368,146Edward E Partridge · University Of Alabama At Birmingham · P30 · FY2009 · CA
Studies of Materials with Physiological Properties
$1,366,000Harvard University · R01 · FY2003 · GM
Loma Linda University Center for Health Disparities Res*
$1,359,173Marino De Leon · Loma Linda University · P20 · FY2008 · MD
Multimodal Investigation of Cellular Adaptation Across Timescales
$1,358,408David Pincus · University Of Chicago · RM1 · FY2025 · GM
Preclinical drug development in pancreatic cancer
$1,356,844Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Molecular Mechanisms Of Growth Control And Carcinogenesis
$1,349,334J. Silvio Gutkind · National Institute Of Dental & Craniofacial Research · ZIA · FY2015 · DE
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy
$1,348,474Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
$1,342,869Marcela Valderrama Maus · Massachusetts General Hospital · UG3 · FY2024 · CA
Development of new antibody-based cancer therapies
$1,340,134Mitchell Ho · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,336,014Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2019 · CA
Molecular Response and Imaging-based Combination Strategies for Optimal PDT
$1,334,595Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2013 · CA
Molecular Response and Imaging-based Combination Strategies for Optimal PDT
$1,334,228Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2011 · CA
TLR Signal Inhibition: A Novel Therapeutic Paradigm
$1,330,773Leonard D Kohn · Interthyr Corporation · R42 · FY2009 · AI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models
$1,327,446Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Therapeutic evaluation in ovarian and breast cancer GEMGDA models
$1,323,540Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
TLR Signal Inhibition: A Novel Therapeutic Paradigm
$1,322,092Leonard D Kohn · Interthyr Corporation · R42 · FY2010 · AI